Microbiome

An average person contains 30 trillion human cells, but even more microbes – about 39 trillion. In addition, there are possibly ten times that number of viral particles in the human virome. Understanding an individual’s microbiome is becoming increasingly important for diagnosing a broad range of diseases.

Patents that relate to the microbiome often need to be drafted differently from patents covering small molecule drugs or conventional diagnostics. For instance, some inventions lie in a way of affecting or detecting a heterogenous population of microbial cells. The cells could be defined in various ways, such as by their function or by their degree of genetic relatedness to a reference organism. Other inventions lie in a way of assessing the impact of the heterogenous population of microbes on drug metabolism, which might require functional definitions and/or specific assays to be written into the claims.

Applicants for microbiome-based patents need to be aware of legal obstacles in certain jurisdictions that would make certain claims very difficult to obtain. At Mewburn Ellis LLP, our world class training and broad experience makes us an excellent choice to be your creative, trusted advisors in this rapidly developing space.

To find out more, view our spotlight page here.

Open pages of EPO Opposition Trends in the Life Sciences Sector

Opposition Trends in the Life Sciences Sector

Special Report

In spring 2019, Mewburn Ellis undertook 350 hours of research, analysing more than 5,000 opposition cases filed at the European Patent Office over the last ten years, studying the timelines for hundreds of life sciences oppositions both before and after the EPO’s opposition streamlining initiative.

View the 2020 addendum for this report, based on information as it appeared on the EPO Register on 10 January 2021 and from bulk data sets extracted on this date.

Download the Report

Read our Blogs

Resistance is futile – how new tech tackles AMR

Resistance is futile – how new tech tackles AMR

by Emily Lythell

Antimicrobial resistance (AMR) refers to the ability of microorganisms—bacteria, viruses, fungi, and parasites—to evolve and resist the effects of drugs that once effectively killed or inhibited ...

UPC Weekly - UPC dials up the advantages for patentees

UPC Weekly - UPC dials up the advantages for patentees

by Matthew Naylor

2024 Week 46 We report this week on two new UPC decisions that make the UPC an even more attractive choice for patent holders seeking to enforce their European patents. The headlines are that: (i) ...

Cambiotics: a novel treatment for PFAS ‘forever chemicals’

Cambiotics: a novel treatment for PFAS ‘forever chemicals’

by Eliot Ward

PFAS are toxic pollutants causing health problems globally. There is currently no treatment. Now a Danish startup is producing a probiotic, which it claims, flushes out the toxins via natural ...

UPC Weekly - NJOY duel with Juul

UPC Weekly - NJOY duel with Juul

by Matthew Naylor

2024 Week 45 5 November 2024 saw two decisions handed down by the UPC Paris Central Division (CD) in revocation actions filed by NJOY against two related Juul patents. In the first decision, against ...

AI designer enzymes

AI designer enzymes

by Isobel Fisher

During the announcement of the first survey of the entire human genome by the Human Genome Project, Dr Francis Collins commented that “many tasks lie ahead if we are to learn how to speak the ...

UPC Weekly - All of the fizz and none of the squeeze

UPC Weekly - All of the fizz and none of the squeeze

by Matthew Naylor

2024 Week 44 SodaStream v Aarke is a decision on the merits of an infringement case based on EP 1793917 B1. The main interesting points come from the court’s interpretation of the claims in view of ...

Learn More
Forward Magazines Overlapping 8

Mewburn Ellis

FORWARD MAGAZINE

Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.